BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.